NCT07472153RecruitingPhase 2/3
PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer
To Validate, Develop and Implement The Scope of Medical Care for Metastatic, Persistent and Recurrent Cervical Cancer Using The Method of Chemoimmunotargeted Therapy
Source: ClinicalTrials.gov · Last updated 28 May 2026
Brief summary (registry, in English)
This is a randomized trial evaluating the results of using of PD-1 and PD-L1 immune checkpoint inhibitors combined with chemotherapy, with or without bevacizumab, in patients with metastatic, persistent, and recurrent cervical cancer.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 2 Mar 2026
- Start date
- 1 Jul 2025
- Primary completion date
- 30 Jun 2030
- Lead sponsor
- N.N. Alexandrov National Cancer Centre
- Diseases
- Cervical cancer
- NCT number
- NCT07472153
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 120
- From 1 Jul 2025 to the primary completion date, 30 Jun 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of another active malignant invasive neoplasm.
Other
- Pregnancy or lactation period.
Who the study is looking for
- Age ≥18-≤75 years.
- Histologically confirmed diagnosis.
- One of the forms of the cervical cancer:
- Metastatic cervical cancer (stage IVB according to FIGO (International Federation of Gynaecology and Obstetrics) 2018);
- Persistent cervical cancer (primary incurability after radical treatment for stages IIB-IVA cervical cancer according to FIGO 2018);
- Reccurent cervical cancer (first recurrence after completed radical treatment for IA-IVB cervical cancer according to FIGO 2018).
- Availability of material for determining PD-L-1 expression for immunotherapy candidates.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- No contraindications to chemotherapy, immunotherapy, or bevacizumab.
- Signed informed consent to participate in the study.
Age in the registry: 18 years to 75 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| N.N. Alexandrov National Caner Centre Coordinator of this site? Confirm its status | Minsk | Belarus | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.